Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ryanair Holdings plc (RYAAY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Ryanair Holdings plcTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Ryanair Holdings plc vs Vertex Pharmaceuticals Incorporated — how do they compare? Ryanair Holdings plc trades at $60.24 (market cap $29.63B), while Vertex Pharmaceuticals Incorporated trades at $529.62 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 4.5× Ryanair Holdings plc's market cap, and Ryanair Holdings plc pays a 1.51% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.

RYAAYVRTX
Market Cap
$29.63B$134.25B
Sector
IndustrialsHealth
52-Week High
$73.82$529.65
52-Week Low
$53.24$376.62
Enterprise Value
$26.61B$128.37B
Dividend Yield
1.51%

Returns comparison

Trailing returns across standard periods

About Ryanair Holdings plc

Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.

Read more on RYAAY

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX